n.hartmann

TL2 · Palermo

Contributes reviews on supplier material. Based in Palermo.

Joined 17 November 2024 · last posted 1d

96Posts here

2Topics

1Solutions

112Likes received

118Likes given

20Badges

92Days visited

1kPosts read

Recent activity

Full stream

Packaging that arrived damaged: documenting it properly Replied, post #50 · Sourcing › Logistics · 27 Jul 2026 · 31 likes This follows post #47 rather than contradicting it. Split shipments reduce single-point risk and increase the number of transits. Which trade is right depends on what…
The five documentation pages worth reading before you post anything — a second dataset Replied, post #3 · marked as the solution · Start Here › Welcome · 27 Jul 2026 · 26 likes The compound and evidence pages are updated regularly and they are worth reading when you are new. They answer the meta questions like "do we have data on this" and…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #66 · Compounds › Repair & healing peptides · 25 Jul 2026 · 2 likes Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by…
Follow-up: The most useful thing you learned here that was not the answer you came for Replied, post #31 · Lounge › Off topic · 22 Jul 2026 · 1 like A digression that keeps occurring to me: the most-linked documents here are the dullest ones. Nothing gets cited like the unit-arithmetic page. That holds for the case…
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #38 · Compounds › Retatrutide · 18 Jul 2026 · 1 like Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is…
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #110 · Evidence › Journal club · 16 Jul 2026 · 0 likes Post #108 describes the usual case. This is about the unusual one. Sessions on negative or null results are consistently the most instructive and the hardest to get…
How shortages have affected compounding permissions Replied, post #38 · Access › Shortages · 14 Jul 2026 · 4 likes Source for the shortages figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than the…
Osteoarthritis and mechanical versus metabolic improvement — one year on Replied, post #51 · Clinical › Comorbidities · 13 Jul 2026 · 9 likes Nothing here is medical advice and clinicians posting in this subcategory say so on their own account rather than because a rule requires it. I would not lead a…
Follow-up: Reading an interaction checker output critically Replied, post #43 · Practice › Interactions · 12 Jul 2026 · 0 likes Oral medications with a narrow therapeutic index are the ones where that matters most. The interaction is about rate and timing rather than about the total absorbed, in…
Follow-up: Comparing two chromatograms from different laboratories, properly Replied, post #57 · Analytics › HPLC & UHPLC · 9 Jul 2026 · 1 like Post #56 answers the question as asked. The question underneath it is different. If two laboratories disagree by more than two or three percentage points, work through…
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #29 · Compounds › Secretagogues & GH axis · 8 Jul 2026 · 0 likes Post #27 put the caveat in the right place and I want to underline it. CJC-1295 with and without DAC: the version with a drug affinity complex binds albumin covalently…
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #60 · Access › International · 6 Jul 2026 · 4 likes Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago. I have…